The introduction of amivantamab presents a exciting development for individuals battling cancers exhibiting c-MET dysregulation. This novel antibody, a targeted agent of both MET kinase and human epidermal growth https://lewiswiry444971.pointblog.net/amivantamab-a-new-hope-for-c-met-associated-tumors-92278095